RNA-seq and flow-cytometry of conventional, scalp, and palmoplantar psoriasis reveal shared and distinct molecular pathways.

Permalink
https://escholarship.org/uc/item/2p10q0s7

Journal
Scientific reports, 8(1)

ISSN
2045-2322

Authors
Ahn, Richard
Yan, Di
Chang, Hsin-Wen
et al.

Publication Date
2018-07-27

DOI
10.1038/s41598-018-29472-w

Peer reviewed
RNA-seq and flow-cytometry of conventional, scalp, and palmoplantar psoriasis reveal shared and distinct molecular pathways

Richard Ahn1, Di Yan1,2, Hsin-Wen Chang1, Kristina Lee1, Shrishti Bhattarai1, Zhi-Ming Huang1, Mio Nakamura1, Rasnik Singh1, Ladan Afifi1, Keyon Taravati1, Priscila Munoz-Sandoval1, Mariela Pauli1, Michael D. Rosenblum1 & Wilson Liao1

It has long been recognized that anatomic location is an important feature for defining distinct subtypes of plaque psoriasis. However, little is known about the molecular differences between scalp, palmoplantar, and conventional plaque psoriasis. To investigate the molecular heterogeneity of these psoriasis subtypes, we performed RNA-seq and flow cytometry on skin samples from individuals with scalp, palmoplantar, and conventional plaque psoriasis, along with samples from healthy control patients. We performed differential expression analysis and network analysis using weighted gene coexpression network analysis (WGCNA). Our analysis revealed a core set of 763 differentially expressed genes common to all subtypes of psoriasis. In contrast, we identified 605, 632, and 262 genes uniquely differentially expressed in conventional, scalp, and palmoplantar psoriasis, respectively. WGCNA and pathway analysis revealed biological processes for the core genes as well as subtype-specific genes. Flow cytometry analysis revealed a shared increase in the percentage of CD4+ T regulatory cells in all psoriasis subtypes relative to controls, whereas distinct psoriasis subtypes displayed differences in IL-17A, IFN-gamma, and IL-22 production. This work reveals the molecular heterogeneity of plaque psoriasis and identifies subtype-specific signaling pathways that will aid in the development of therapy that is appropriate for each subtype of plaque psoriasis.

While the skin lesions of plaque psoriasis are described classically as well-circumscribed, raised, erythematous lesions with overlying silvery scale, there is considerable heterogeneity in the clinical presentation of the disease. The anatomic location of psoriatic lesions, time course (chronic vs. acute), age of onset (adult vs. pediatric), lesion morphology (plaque size, induration, erythema, and scale), and response to therapy may vary from patient to patient. This varied spectrum of clinical phenotypes suggests that psoriasis may comprise a collection of several different biologic subtypes, which while sharing certain common features, may also have unique immunogenetic characteristics. While "conventional" plaque psoriasis typically affects the trunk and extensor surfaces (elbows/knees), other patterns of lesion distributions such as scalp and palmoplantar psoriasis are recognized as clinically distinct subtypes of plaque psoriasis1. Scalp and palmoplantar psoriasis may each occur in isolation or with other psoriasis subtypes, but tend to be more refractory to treatment compared to conventional plaque psoriasis.2,3 These two subtypes are also associated with a higher burden of disease that is both greater than conventional psoriasis and disproportionate to the body surface area affected4. For instance, patients with scalp and palmoplantar psoriasis report greater physical and psychosocial impairment from their disease compared to patients with the conventional plaque form of psoriasis5,6. Although physicians recognize the clinical differences between these subtypes, little is known about the molecular and transcriptomic differences between conventional, scalp, and palmoplantar psoriasis.
palmoplantar psoriasis, especially with respect to key populations of immune cells. In this study, we use RNA-seq to assess the transcriptomic differences between scalp, palmoplantar, and conventional psoriasis and use flow cytometry to profile the cytokines secreted by CD4+ T effector cells, CD8+ T effector cells, and CD4+ regulatory T cells (Tregs).

Methods

Study population. We recruited 8 patients with conventional plaque psoriasis (CP) on the trunk and extremities, 8 patients with scalp psoriasis (SP), and 3 patients with plaque-type palmoplantar/handfoot psoriasis (HF) from the San Francisco Bay area. Subjects were adults over the age of 18 who had a diagnosis of psoriasis from a board certified dermatologist for at least 6 months (mean duration = 19.9 years) and who were not on systemic treatments. For subjects on topical therapy, the sampled plaque was free of topical therapy for at least 2 weeks prior to the biopsy procedure. Normal healthy skin from the surgical discards of 9 cosmetic surgery patients was used as controls (C). Skin from surgical discards came from the trunk or upper legs. This study was approved by the University of California, San Francisco’s institutional review board and all subjects provided written informed consent prior to enrollment. All subjects were de-identified and any HIPAA identifiers were removed.

Skin biopsies. Two 4-mm punch biopsies were obtained from the lesional skin of each psoriasis patient, with one biopsy used for RNA-seq and the other for flow cytometry. Biopsies of conventional plaque psoriasis were taken from lesions on the arms or legs. Tissue samples were placed either into RNALater solution or onto sterile gauze that had been dampened with phosphate buffered saline and stored at 4 °C until further processing by flow cytometry.

RNA sequencing. RNA was extracted from one 4-mm punch biopsy specimen for bulk RNA sequencing with the Qiagen Allprep DNA/RNA mini kit. The Agilent 2100 bioanalyzer was used to perform quality control and identify samples with a high proportion of minimally degraded mRNA (defined as an RNA integrity number >7.500 pg). Samples that passed quality control underwent library preparation using the Ovation RNA-Seq System V2 protocol (Nugen) or the Ribozero (Illumina) kits. Paired-end sequencing with read length of 100 bp was conducted using the Illumina Hiseq platform.

Read quality was checked using FastQC v. 0.11.4. Reads were aligned to the UCSC hg19 human reference genome using STAR v. 2.4.2. Principal components analysis was performed to detect outliers and any batch effect (Fig. 1). For the RNA-seq analysis only, we removed 2 healthy controls, 3 CP, and 2 SP samples due to sequencing batch effect. The ComBat function in the sva package was implemented to adjust for residual sequencing batch effect of the remaining samples. The Cufflinks package v. 2.2.1 was implemented to perform normalization and test for differential expression. BioVenn was implemented to create an intersectional plot of differentially expressed genes in each psoriasis subtype.

Network analysis. We performed further quality-control on the matrix of normalized expression values to remove any transcripts with either zero variance or a missing value prior to performing weighted gene coexpression network analysis (WGCNA). We implemented the WGCNA package to create a weighted adjacency matrix. The soft thresholding parameter, β, for the power function was set to 12 after a sensitivity analysis of scale-free topology was performed (Supplementary Fig. 1). This weighted adjacency matrix was used to generate a topological overlap matrix (TOM) and dendrogram. A dynamic hybrid branch cutting method was implemented on the resulting TOM-based dendrogram to identify modules. A cut height of 0.3 was set to merge module...
**Results**

**Patient demographics.** A summary of patient demographic characteristics is provided in Table 1. Age, psoriasis age of onset, and body mass index (BMI) were comparable among subjects with conventional psoriasis, scalp psoriasis, and healthy controls. For gender, the control group had a higher proportion of female subjects compared to the conventional plaque group. The palmoplantar psoriasis group was not included in the statistical analyses due to small sample size. *p ≤ 0.05.

**RNA sequencing.** Differential expression analysis revealed core set of shared genes involved in conventional, scalp, and palmaroplantar psoriasis. Differential expression analysis revealed 2297 differentially expressed (DE) genes (DEGs) in CP vs C, 2319 DEGs in SP vs C, and 1318 DEGs in HF vs C ([log2(FC)] ≥ 1 and q ≤ 0.05; Table 2, Supplementary Table 1). An intersection of all DEGs from CP vs C, SP vs C, and HF vs C revealed a core set of 765 DEGs common to each subtype of psoriasis (Fig. 2, Supplementary Table 2). Top DEGs from this core set include genes such as S100A7A, SPPR2/B, SERNPB4, S100A9, KRT6, C10orf99, LCE3/E, IL36G, and OASL, which have been found to be DE in previous studies of CP12,13, SP14, and HF15. A heatmap of this core set of DEGs reveals a clear distinction between psoriasis and healthy control samples (Fig. 3). Interestingly, this core set of genes also results in differential clustering of psoriasis subtypes, suggesting that these core genes may have different expression levels among psoriasis subtypes. Top Ingenuity Pathway Analysis (IPA; www.qiagen.com) canonical pathways eigengenes (ME; first principal component of each network) that have a correlation of 0.7 or greater. We then estimated MEs, which are the first principal components for each gene expression module after a singular value decomposition is performed on the TOM. We calculated gene significance, defined as $G_{S_i} = \langle	ext{cor}^*(x_i, t)\rangle$, where $x_i$ is the $i$-th gene and $t$ is the binary indicator variable for phenotype. We also calculated the ME significance, defined as $M_{E_j} = \langle\text{correlation}(ME_{i,j})\rangle$, where $ME_{i}$ is the $j$-th ME. Module membership, MM, for the $i$th gene was defined as $MM = \langle\text{correlation}(x_i, ME)\rangle$.

**Flow cytometry.** One 4 mm skin punch biopsy was taken from each patient and immediately stored at 4°C in a container with sterile glove and PBS until it was ready to be processed. The tissue was trimmed to remove hair and subcutaneous adipose before being finely minced and mixed with digestion buffer composed of Collagenase Type IV (Worthington LS04188), DNAse (Sigma-Aldrich DN25-1G), 10% FBS, 1% HEPES, and 1% Penicillin/Streptavidin in RPMI 1640. After overnight incubation in 5% CO₂, cell suspensions were harvested, filtered, centrifuged, and counted. Cells were then stimulated and incubated for 4 hours with Cell Stimulation Cocktail 500× (Tonbo biosciences; TNB-4975). Cells were stained with viability dye Ghost Dye™ Violet 510 (Tonbo biosciences 130870) and the following antibodies: anti-hCD3 PerCP (Biolegend; SK7), anti-hIL-13 FITC (eBioscience; 85BRD), anti-hTNF-α PE-Cy7 (BD Pharmigen; MAb11), anti-hCD4 PE-Texas Red (Invitrogen; S3.5), anti-hIL-22 PE (R&D Systems; 142928), anti-hCD45 APC-eFluor 780 (eBioscience; 2D1), anti-hIFN-γ Alexa Fluor 700 (Biolegend; 4S.B3), anti-h-IL-17A eFluor 660 (eBioscience; eBio64CAP17), anti-Foxp3 eFluor 450 (eBioscience; PCH101), and anti-hCD8a eVolve 605 (eBioscience; RPA-T8). We then performed multi-parameter flow cytometry to subset the leukocyte population into defined T cell populations (CD4+ T effectors, CD8+ T cells, and CD4+ Foxp3+ Tregs) based on cell surface and intracellular differentiation/activation markers and quantified the cytokines produced by each cell type. Data was acquired using the LSR Fortessa (BD Biosciences) flow cytometer and results were analyzed using FlowJo software platform (Tree Star Inc.) (Supplementary Fig. 2).

**Statistical analysis.** Cytokine and chemokine levels were compared with the Mann-Whitney U test in GraphPad Prism 7.

**Data Availability Statement.** RNA-seq data generated from this study has been deposited in Gene Expression Omnibus and are accessible through GEO Series accession number GSE117405 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117405).
enriched for with the core DEGs include “Endothelin-1 Signaling”, “p38 MAPK Signaling”, “MIF Regulation of Innate Immunity”, and “Atherosclerosis Signaling” ($-\log(p\text{-value}) \geq 1.3$; Fig. 4A, Supplementary Table 3).

Conventional psoriasis transcriptome. Top up-regulated DEGs in CP vs C include previously identified psoriasis-associated genes such as $\text{IL36A/G}$, $\text{SPRR2A/B/F}$, $\text{SERPINB4}$, $\text{S100A7A}$, $\text{S100A9}$, and $\text{IL17F}$ while top down-regulated DEGs include $\text{SERTM1}$, $\text{IL6}$, and $\text{ADAMTS16}$ (Supplementary Table 1). Amongst the 2297 DEGs in CP vs C, 605 DEGs were exclusive to CP vs C (Supplementary Table 4). Amongst these CP vs C exclusive genes, top up-regulated genes include $\text{SST}$, $\text{TTTY14}$, $\text{PRKY}$, $\text{IL20}$, $\text{KRT33A}$, and $\text{HOXD11}$ while top down-regulated

| Comparison (A vs B) | Number DEGs* | Up-regulated in A | Down-regulated in A |
|---------------------|--------------|------------------|---------------------|
| CP vs C             | 2319         | 1119             | 1200                |
| SP vs C             | 2297         | 1128             | 1169                |
| HF vs C             | 1318         | 774              | 544                 |

Table 2. Number of differentially expressed genes (DEGs) in CP vs C, SP vs C, and HF vs C. *$|\log_2(\text{FC})| \geq 1$ and $q \leq 0.05$.

Figure 2. Venn diagram showing the number of core DEGs, which are the intersection of DEGs between HF vs C, CP vs C, and SP vs C. Circles are sized according to the number of DEGs in each test and the size of the intersections are sized according to the number of intersections between each test.

Figure 3. A heatmap of the gene expression of the core 763 DEGs, showing clear separation between all subtypes of psoriasis and healthy controls and clustering of subtypes of psoriasis.
genes include SERTM1, ADAMTS16, MATN4, and HAS1. IPA canonical pathways enriched for amongst these CP vs C exclusive DEGs include “GP6 Signaling Pathway”, “Wnt/B-catenin Signaling”, “mTOR Signaling”, and “B Cell Receptor Signaling” (−log (p-value)

Figure 4. Barplots of Ingenuity Pathway Analysis canonical pathways enriched for in the Core DEGs (A), CP vs C (B), SP vs C (C), HF vs C (D).

Scalp psoriasis transcriptome. In SP vs C, a majority (1543/2319 or 67%) of the DEGs were also differentially expressed in CP vs C, including known CP signature genes such as S100A7A, SPRR2B, IL36A/G, IL17D/F/RD/RE and SERPINB4. Keratin (KRT-) and keratin-associated protein (KRTAP-) family genes were also highly expressed in SP and in many cases, DE between SP and C, much more so than in CP or HF. While these KRT- and KRTAP-genes are likely to be highly important in the normal development of hair follicles and hair, results from a previous study of SP by Ruano et al.14 that compared lesional scalp tissue to normal scalp tissue did not find evidence that keratin or keratin-associated protein genes are DE. Nevertheless, 197/1128 of the up-regulated genes in SP were also up-regulated in SP skin in Ruano et al.14. 632 of the DEGs were exclusive to SP vs C and included top up-regulated genes LCE3C, FAM26D, and CBLN2 while top down-regulated genes included AGR3, TBX5, and HOXA10 (Supplementary Table 4). Top IPA canonical pathways enriched for in DEGs unique to SP include “Androgen Biosynthesis”, “Inflammasome Pathway”, and “Osteoarthritis Pathway” (−log (p-value) ≥ 1.3; Fig. 4B, Supplementary Table 3).

Palmoplantar psoriasis transcriptome. Relative to SP and CP, HF was transcriptomically closest to C and nearly 60% of the 1318 DEGs in HF vs C are members of the core set of DEGs common to all subtypes of psoriasis. In contrast, only about 33% of the DEGs in CP vs C and SP vs C are members of the psoriasis core DEG set. Of the 1318 DEGs, 262 were unique to HF vs C with top up-regulated genes including S100A7, NEFL, and SERPINB3 while top down-regulated genes included KRT25, TCHH, and CDH22 (Supplementary Table 4). Top IPA canonical pathways enriched for in DEGs unique to HF revealed that the top enriched pathways include “Serine Biosynthesis”, “Graft-versus-Host Disease Signaling”, and “Semaphorin Signaling in Neurons” (−log (p-value) ≥ 1.3; Fig. 4C, Supplementary Table 3).

Weighted gene co-expression network analysis (WGCNA) reveals SP and HF specific networks of co-expressed genes. To identify genes that are co-expressed within networks of genes correlated with each subtype of psoriasis, we performed a weighted gene co-expression network analysis (WGCNA). After construction of the co-expression network and subsequent branch pruning, we were left with 28 networks (Fig. 5). As WGCNA is an unsupervised learning method, to determine which networks are associated with each specific sub-type of psoriasis, we calculated the module eigengene (ME), or the first principal component of each network, and performed a Pearson correlation between each ME and CP, SP, and HF. We found 2/28 modules significantly correlated modules (Pearson \( \rho > = 0.7 \) and \( q < 0.05 \)), one correlated with SP (\( q = 8.31 \times 10^{-7} \)) and one with HF (\( q = 6.05 \times 10^{-4} \)).
As the ME is the first principal component of a module, it can be seen as a proxy for the overall expression profile of a given module. The two modules that are correlated with SP and HF, respectively, are the yellow ($n_{\text{genes}} = 1200$) and lightcyan ($n_{\text{genes}} = 260$) modules (see Supplementary Table 4 for all genes in each module).

Barplots visually capture the distinct patterns of expression in the SP and HF modules (Fig. 6A,B). The canonical pathways that the SP module hub genes were significantly enriched for were "Glucocorticoid Receptor Signaling", "Protein Citrullination", and "1,25-Dihydroxyvitamin D3 Biosynthesis" while the canonical pathways that the HF module hub genes were significantly enriched for were "Pregnenolone Biosynthesis", "Histidine Degradation VI", and "Ubiquinol-10 Biosynthesis" ($-\log (p\text{-value}) \geq 1.3$).

To identify the most influential genes within each module, or the "hub" gene, we calculated the module membership (MM) for each gene. We used a threshold of $\text{MM} \geq 0.8$ to identify hub genes and identified 58 hub genes in the HF module and 361 hub genes in the SP module (see Supplementary Table 5 for all hub genes). Some of the most influential genes within the HF module, such as $\text{NEFL}$ and $\text{ALOX15}$ are DEGs in HF vs C. However, a majority of the hub genes were not DE in any of the comparisons.

Flow Cytometry Profiles. Psoriatic skin vs healthy skin. We first examined whether there were commonalities between all three subtypes of psoriasis and healthy skin. In terms of T cell composition, the percentage of CD4+ Tregs out of total T cells was consistently higher in each of the three psoriasis subtypes compared to control skin, whereas the percentage of CD4+ T effectors was lower than control skin, and percentage of CD8+ T effectors the same as control skin (Figs 7A and 8A). Furthermore, the percentage of TNF-α derived from CD8+ T cells, CD4+ T effectors, and CD4+ Tregs, were significantly higher in conventional plaque and scalp psoriasis than in control skin (Figs 7B, 8B and 9B). CP and SP also had a higher percentage of IL-17A from CD8+ T cells...
and CD4+ T effectors than control skin (Figs 7C and 8C). There was a trend towards an increased percentage of IL-17A from CD4+ Treg cells in psoriatic skin (Fig. 9C). All three psoriasis subtypes had significantly lower IL-13 from CD4+ T effector cells compared to healthy control skin (Fig. 8E). The higher percentage of IL-13 from psoriatic CD4+ Tregs was significant or nearly significant compared to control Tregs (Fig. 9E).

**Differences between psoriasis subtypes.** Conventional plaque psoriasis had a significantly higher percentage of IL-17A and TNF-α from CD8+ T cells relative to palmoplantar psoriasis (p = 0.044 and p = 0.044 respectively)
Figure 7B,C). Plaque psoriasis also had more IL-17A and IFN-γ double producers than palmoplantar psoriasis ($p = 0.044$) (Fig. 10). Conventional plaque psoriasis had a significantly higher percentage of IFN-γ from CD4+ T cells and CD8+ T cells compared to controls ($p = 0.021$ and $p = 0.015$, respectively), while patients with scalp psoriasis did not differ appreciably from controls (Figs 7F and 8F). In contrast, only scalp psoriasis had a higher percentage of IL-22 from CD8+ T cells relative to controls ($p = 0.029$) (Fig. 7D).

Differential expression between high and low IL-17A producing CD8+ T cells. Differential expression analysis between samples with a high and low proportion of IL-17A producing CD8+ T cells (IL17A HI and IL17A LO, respectively—see Fig. 7C) revealed 83 genes differentially expressed ($|\log_2(FC)| \geq 1$ and $q \leq 0.05$) between IL17A HI and IL17A LO samples, including 25 up-regulated in the IL17A HI group (see Supplementary Table 6 for a full list of differentially expressed genes; Supplementary Fig. 3). Top up-regulated genes include SFRP4, which was interestingly found to be down-regulated in psoriasis skin 16, and CCL13, which was also found to be down-regulated in lesional psoriasis skin 17.

Figure 9. Percentage of CD4+ T regulatory cells and CD4+ T regulatory cell derived cytokines in healthy skin and lesional skin from conventional plaque, scalp, and hand foot subtypes of psoriasis. Bars represent the median and interquartile range.

Figure 10. Percentage of IL-17, IFN-γ double producers in the lesional skin of the conventional plaque, scalp, and hand foot subtypes of psoriasis.
Discussion

RNA-seq analysis. In our analysis, we identified a core set of psoriasis genes that are common to CP, SP, and HF. These genes include genes that are well known to be involved in psoriasis, including LCE3B, LCE3E, SERPINA6, and S100A7A, genes involved in activation and proliferation of keratinocytes, modulation of host immune response, and antimicrobial defense. Notably, two members of the IL-1 superfamily of cytokines are represented, including IL36B and IL36G. IL-34, a cytokine that has recently been found to be elevated in the serum of psoriasis patients (particularly those with psoriatic arthritis)\(^3\), was the only other interleukin cytokine that was in the core set. Recently, much attention has been focused on the role of IL-36 genes in psoriasis pathogenesis, especially as a biomarker\(^4\) and as a potential therapeutic target\(^5\). IL-36 cytokines have been shown to trigger the activation of the NFκB pathway as well as the mitogen-activated protein kinase (MAPK) pathway, one of the top canonical pathways enriched for with the core DEGs. Most recently, Arakawa et al.\(^6\) demonstrated that IL-36 signaling facilitates the Th17 responses in generalized pustular psoriasis. IL36B and IL36G are both in the core set of DEGs and highly up-regulated in each form of psoriasis. Interestingly, IL36RN, the gene encoding the IL-36 receptor antagonist, is also highly up-regulated in all forms of psoriasis.

One of the top IPA canonical pathways enriched for with the core set of DEGs is endothelin-1 signaling. Endothelin-1 is a peptide produced by endothelial cells with systemic vasoconstrictor properties that is associated with mitogenic action in smooth muscle cells as well as endothelial cells. Within the skin, endothelin-1 is present and functions within the microvasculature. Cecchi et al.\(^7\) observed that patients with psoriasis had much higher serum plasma levels of endothelin-1 and more recently, Borska et al.\(^8\) also observed higher serum plasma levels of endothelin-1 in psoriasis patients versus healthy control patients. Nakahara et al.\(^9\) recently discovered that endothelin-1 polarizes the dendritic cell – T cell response towards Th17/Th1 differentiation and induces dendritic cell production of pro-inflammatory cytokines such as IL-12, IL-23, and IL-6. They also showed via immunohistochemical that endothelin-1 is expressed primarily in basal keratinocytes and more highly expressed in severe cases of psoriasis.

Regarding scalp psoriasis, our results are similar to those of Ruano et al.\(^14\), who concluded that the SP transcriptome is similar to the CP transcriptome but with more prominent expression of key psoriatic genes in CP. We found that not only was the direction of expression of the overlapping DEGs between CP vs C and SP vs C the same, but also that the mean FPKM value for these overlapping DEGs was slightly higher in CP (mean = 48.7) than in SP (mean = 45.0). One of the key genes in the top unique SP vs C pathways was AKR1C3. Aldo-keto reductase 1C3 (AKR1C3) is a gene that is expressed in the epidermis that mediates the metabolism of steroid hormones and has been shown to affect keratinocyte differentiation and is up-regulated in atopic dermatitis\(^25\) but not in psoriasis. Interestingly, AKR1C3 is significantly down-regulated in SP vs C.

In palmoplantar psoriasis, a number of the up-regulated genes in HF in our study were found to be up-regulated in normal palmoplantar skin (relative to normal non-palmoplantar skin) in a previous study by Bissonette et al.\(^15\), including S100A7/8/9, DEFB4A/B, P13, IL36G, SERPINB4, and KRT9. While many of these up-regulated genes in normal palmoplantar skin (relative to normal non-palmoplantar skin) were also found to be up-regulated in HF skin by Bissonette et al.\(^15\), 16 of these up-regulated genes in normal palmoplantar skin—including genes up-regulated in CP such as KRT9, KRT16, S100A7, S100A8, and WNT5A—were not DE in their comparison between HF and normal palmoplantar skin. Two of the most up-regulated genes in Bissonette et al.\(^15\), GPRIN1 and ADAM23, were also up-regulated in HF vs C. However, neither of these genes were amongst the top-most up-regulated genes in HF in our analysis. Semaphorin-4D (SEMA4D; also known as CD100) is a key gene in the top HF vs C pathway, “Semaphorin Signaling in Neurons”, which was significantly up-regulated in HF vs C. Interestingly, Zhang et al.\(^26\) recently showed that SEMA4D promotes inflammation by activating the NFκB and inflammasome pathways in keratinocytes. IL33 is a key gene in the HF vs C pathway, “Graft-versus-Host Disease Signaling” that was amongst the newly identified interleukin cytokines involved in psoriasis by Li et al.\(^18\) that was found to be elevated in the serum of psoriatic and psoriatic arthritis patients. However, we found that IL33 is significantly down-regulated in HF.

T cell production of TNF-α and IL-17A. Based on our flow cytometry data, TNF-α appears to have a central role in the pathogenesis of all plaque subtypes. Previous studies have demonstrated elevated levels of TNF-α in the serum\(^27,28\) and skin of psoriasis patients\(^3\). Moreover, anti-TNF-α biologics are an effective treatment for psoriatic disease. Our study shows that CD8+ T cells, CD4+ T effectors, and CD4+ Tregs all contribute to an increase in TNF-α in psoriatic skin, suggesting multiple elements of immune dysfunction. While keratinocytes do not respond only to TNF-α, high levels of TNF-α in conjunction with elevated IL-17A stimulate keratinocyte hyperproliferation and drive the inflammatory feedback loop in psoriasis\(^29\). In psoriasis, TNF-α is thought to work synergistically with IL-17A by inducing IL-17 receptor (IL-17R) expression on keratinocytes, promoting the maturation of Th17 and Th22 cells, and increasing the production of IL-17A\(^3\). In fact, our study shows that IL-17A from CD8+ T cells, CD4+ T effectors, and CD4+ Tregs were also higher in psoriasis samples compared to controls. The increase in TNF-α and IL-17A from CD4+ T effectors is accompanied by an increase in the proportion of CD4+ T effectors in psoriatic skin. These findings likely reflect an expansion of the Th17 subset of CD4+ T effectors, which act as “professional” IL-17A producers that, in psoriasis, create a positive feedback loop with other pro-inflammatory cytokines such as IL-23\(^3\).

However, the increased percentage of CD4+ Treg-derived TNF-α and IL-17A is more surprising. Normally, CD4+ Tregs modulate inflammation and promote tolerance to self-antigens by suppressing the activation and proliferation of CD4+ and CD8+ T cells. However, in a pro-inflammatory environment, Tregs may be converted to a phenotype that co-expresses FOXP3 and RORγt, a transcription factor typically associated with the Th17 lineage\(^3\). These FOXP3+RORγt+ Treg cells have been shown to produce IL-17 and propagate the inflammatory milieu\(^3\). While in our study the trend towards increased Treg-derived IL-17A in psoriasis was not statistically
significant (p = 0.063 conventional plaque, p = 0.16 scalp, p = 0.15 palmoplantar), the relatively small number of patients in our study limited our power. In addition to IL-17A, our study suggests that some pathogenic Tregs may also produce more TNF-α in psoriasis skin, potentiating the effects of IL-17A and contributing further to the inflammatory cascade. Furthermore, there is also an increased percentage of CD4+ Tregs in psoriatic skin. This is consistent with prior studies, which also found that disease severity was inversely correlated with the ratio of Th17 to Treg cells in the skin30. The expansion of Tregs in psoriatic skin suggests an impairment of their typical immunosuppressive functions33. Indeed, studies have shown that in psoriasis, Treg suppression of pathologic effector CD4+ T cells is impaired33,36,37. Tregs may, therefore, be a novel, unexplored therapeutic target for the treatment of plaque psoriasis.

Increases in CD8+ T cell derived TNF-α and IL-17A also intriguing as psoriasis has traditionally been thought of as a Th1/Th17 mediated disease. Elevated numbers of TNF-α and IL-17A producing CD8+ T cells have only recently been found in the skin30,39 and synovial fluid of patients with psoriatic disease36 and their role in the disease process has not been fully elucidated. Interestingly, this population of CD8+ T cells is resistant to immunomodulation by Tregs36. Thus, the production of TNF-α and IL-17A by CD8+ T cells can go unchecked in psoriatic skin, despite a normal percentage of CD8+ T cells relative to controls. In fact, treatment of AGM mice grafted with non-lesional skin from psoriasis patients with 1 mg mAb to human CD8 resulted in complete blockade of psoriasis development, on par with the effect observed with TNF-α inhibitors36. These results suggest that CD8+ T cells may be a potential drug target for reducing TNF-α/IL-17A mediated inflammation.

In our differential expression analysis between the IL17A Hi and the IL17A Lo producing CD8+ T cells, we found that TMPRSS11D and PM20D1 were down-regulated in the IL17A Hi, which Suarez-Farinas et al.41 observed to be down-regulated in lesional psoriasis skin versus healthy control skin. One of the most down-regulated genes in IL17A Hi was IL36B, a cytokine that Li et al.32 discovered down-regulated signature keratinocyte genes. Interestingly, we did not find evidence of differential expression of IL17A, IL13, IFNG, or IL22 (TNF-α was not detected in our RNA-seq analysis). We believe that bulk RNA-seq does not provide sufficient resolution to detect cytokine expression differences across different T cell populations. Indeed, we have recently shown42 that populations such as CD8+ T cells are not well represented in bulk RNA-seq analysis of skin tissue.

**T cell production of IL-22.** IL-22 is an inflammatory cytokine produced Th22 cells that facilitates the recruitment of immune cells to the skin and disrupts keratinocyte maturation, causing acanthosis and parakeratosis in psoriatic skin lesions34. Although TNF-α promotes the maturation of Th22 cells and previous studies have found elevated IL-22 in psoriasis lesions, scalp psoriasis was the only subtype with significantly higher IL-22 and this difference was only significant in the IL-22 derived from CD8+ T cells. This suggests that IL-22 may have different roles in the inflammatory milieu depending on the plaque subtype, which may be due to site-specific variations in the cutaneous microflora and immunobiology45. For example, hair follicle cytokines are thought to modulate memory T cell homeostasis46. In addition, immune microenvironments are present along the follicle and peri-follicular tissue45. This contrasts with findings from a transcriptomic study of lesional and non-lesion psoriatic skin which found similar levels of IFN-γ expression in scalp and non-scalp lesions47. Non-scalp lesions also had a significantly higher activation of genes involved in the TNF/IL-17/IL-22-induced keratinocyte responses, although the production of IL-22 from CD8+ T cells was not quantified. Furthermore, this study sampled scalp and non-scalp lesions from the same subject while our study took scalp and non-scalp keratinocyte responses, although the production of IL-22 from CD8+ T cells was not quantified. Furthermore, this study sampled scalp and non-scalp lesions from the same subject while our study took scalp and non-scalp lesions from different patients47. Alternatively, systemic anti-TNF-α treatment, which is known to reduce IL-2247, may be suppressing IL-22 levels in some patients.

**T cell production of IL-13.** The decrease in CD4+ T effector-derived IL-13 seen in all subtypes of psoriasis is consistent with previous studies and suggests a shift in the Th1-Th2 axis. IL-13 is a cytokine produced predominantly by the Th2 lineage of CD4+ T cells and IL-13 polymorphisms are associated with altered psoriasis susceptibility38. In keratinocytes, IL-13 functions as a negative regulator of Th1 associated IFN-γ and TNF-α pathways via activation of STAT6, SOCS1, and SOCS3. IL-13 has also been shown to inhibit the development of the Th17 subset of effector CD4+ T cells, which are thought to be a major source of IL-17 in psoriatic inflammation32,33. A reduction in IL-13 dependent suppression of Th1 cytokines and a concurrent increase in Th17 cells may help drive psoriatic inflammation37. The shift towards a Th1 dominated cytokine profile is supported by increased levels of IL-13 and IL-17A production from CD4+ T effector cells in psoriasis samples.

**T cell production of IFN-γ.** Conventional plaque psoriasis was the only subtype to demonstrate significantly higher levels of IFN-γ compared to control skin. Elevated CD4+ T effector derived-IFN-γ is consistent with an immune response dominated by Th1 cells, which are the predominant producers of IFN-γ. However, CD8+ T cells also appear to produce higher levels of IFN-γ in psoriatic skin. The source of CD8+ T cell-derived IFN-γ may be the IL-17 secreting CD8+ T cells, which have demonstrated a similar capacity to produce IFN-γ39,40. This shift of CD8+ T cells towards a Th1 cytokine profile may represent an important pathologic mechanism in the development of psoriasis.

**Study limitations.** One of the limitations for our study was the comparison of psoriasis subtypes to healthy control skin from the trunk and extremities. While this did have the advantage of allowing for a comparison of psoriasis subtypes to a common, uniform baseline, it also allows for the possibility that some DEG were detected on the basis of site-specific differences. While we were able to compare our list of DEG from SP vs C against the list of up-regulated genes in SP (relative to normal scalp tissue) from Ruano et al. and determined that excluding KRT- or KRTAP- genes may be appropriate as none of these genes were up-regulated in SP in Ruano et al., this comparison did not include genes that were down-regulated in SP (relative to normal scalp tissue). Finally,
due to our limited sample size and sequencing batch effects, we were not able to stratify our analyses by sex. Future studies with sufficient numbers of gender-balanced samples within each subtype of psoriasis are needed to bolster the findings of this present study.

Conclusion
The results of our study demonstrate that conventional, scalp, and palmoplantar psoriasis share a core set of molecular features, but also exhibit novel differences in gene expression, gene networks, T cell populations, and T cell cytokines. Understanding differences in the immunobiology between clinical subtypes can help us provide more effective, personalized treatment for psoriasis patients.

References
1. Guinot, C. et al. Psoriasis: characterization of six different clinical phenotypes. Experimental Dermatology 18, 712–719 (2009).
2. Adisjen, E., Tekin, O., Gulekon, A. & Gurur, M. A. A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients. *Journal of the European Academy of Dermatology and Venereology* 23, 814–819 (2009).
3. Chan, C. S. et al. Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation. *Journal of the American Academy of Dermatology* 60, 962–971 (2009).
4. Cassano, N., Vestita, M., Apruzzi, D. & Vena, G. A. Alcohol, psoriasis, liver disease, and anti-psoriasis drugs. *International Journal of Dermatology* 50, 1323–1331 (2011).
5. Petley, A. A., Balkrishnan, R., Rapp, S. R., Fleischer, A. B. & Feldman, S. R. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. *Journal of the American Academy of Dermatology* 49, 271–275 (2003).
6. Chung, J. et al. Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis. *Journal of the American Academy of Dermatology* 71, 623–632 (2014).
7. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29, 15–21 (2012).
8. Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. *Bioinformatics* 28, 882–883 (2012).
9. Trapnell, C. et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat Protoc.* 7, 562–578 (2012).
10. Hulsken, T., de Vlieg, J. & Alkema, W. BioVenn – a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams. *BMC Genomics* 9, 488 (2008).
11. Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. *BMC Bioinformatics* 9, 539 (2008).
12. Li, B. et al. Transcriptome Analysis of Psoriasis in a Large Case–Control Sample: RNA-Seq Provides Insights into Disease Mechanisms. *Journal of Investigative Dermatology* 134, 1828–1838 (2014).
13. Keermann, M. et al. Psoriasis: characterization of six different clinical phenotypes. *Journal of Investigative Dermatology* 134, 1323–1331 (2011).
14. Mahil, S. K. et al. New Interleukins in Psoriasis and Psoriatic Arthritis Patients: The Possible Roles of Interleukin-33 to Interleukin-38 in psoriasis vulgaris. Pathway Analysis of Skin from Psoriasis Patients after Adalimumab Treatment Reveals New Events in the Anti-Inflammatory Mechanism of Anti-TNF-α. *PLOS ONE* 11, e0167437–16 (2016).
15. Li, J. et al. New Interleukins in Psoriasis and Psoriatic Arthritis: The Possible Roles of Interleukin-33 to Interleukin-38 in Disease Activities and Bone Erosions. *Dermatology (Basel)* 233, 37–46 (2017).
16. D’Erme, A. et al. BLNAR is a biomarker for psoriasis skin lesions. *J. Invest. Dermatol.* 135, 1025–1032 (2015).
17. Mahil, S. K. et al. An analysis of IL-36 signature genes and individuals with IL1R1/R2 knockout mutations validates IL-36α as a psoriasis therapeutic target. *Science translational medicine* 9 (2017).
18. Arakawa, A. et al. Unopposed IL-36 activity promotes clonal CD4+ T-cell responses with IL-17A production in generalized pustular psoriasis. *Journal of Investigative Dermatology* 1–32, https://doi.org/10.1016/j.jid.2017.12.024 (2017).
19. Cecchi, R., Giomi, A., Ciuti, M., Gironi, A. & Seghieri, G. Increased levels of plasma endothelin-1 in patients with psoriasis. *Clin. Chim. Acta* 226, 113–115 (1994).
20. Borska, L. et al. IL34, EDA, and endothelin-1 in psoriasis vulgaris: pathophysiological functions and potential biomarkers. *Physiol Res.* (2017).
21. Nakahara, T. et al. The pruritogenic mediator endothelin-1 shifts the dendritic cell-T cell response toward Th17/Th1 polarization. *J. Immunol.* 46, 3178–3175 (2017).
22. Arakawa, A. et al. Unopposed IL-36 activity promotes clonal CD4+ T-cell responses with IL-17A production in generalized pustular psoriasis. *Journal of Investigative Dermatology* 1–32, https://doi.org/10.1016/j.jid.2017.12.024 (2017).
23. Cech, R., Giomi, A., Ciuti, M., Gironi, A. & Seghieri, G. Increased levels of plasma endothelin-1 in patients with psoriasis. *Clin. Chim. Acta* 226, 113–115 (1994).
24. Borska, L. et al. IL34, EDA, and endothelin-1 in psoriasis vulgaris: pathophysiological functions and potential biomarkers. *Physiol Res.* (2017).
25. Nakahara, T. et al. The pruritogenic mediator endothelin-1 shifts the dendritic cell-T cell response toward Th17/Th1 polarization. *J. Immunol.* 46, 3178–3175 (2017).
26. Arakawa, A. et al. Unopposed IL-36 activity promotes clonal CD4+ T-cell responses with IL-17A production in generalized pustular psoriasis. *Journal of Investigative Dermatology* 1–32, https://doi.org/10.1016/j.jid.2017.12.024 (2017).
27. Cech, R., Giomi, A., Ciuti, M., Gironi, A. & Seghieri, G. Increased levels of plasma endothelin-1 in patients with psoriasis. *Clin. Chim. Acta* 226, 113–115 (1994).
28. Eder, L. et al. IL13 gene polymorphism is a marker for psoriatic arthritis among psoriasis patients. *Annals of the Rheumatic Diseases* 70, 1594–1598 (2011).
29. Hijken, D. et al. CD8+ T Cells in the Lesional Skin of Atopic Dermatitis and Psoriasis Patients Are an Important Source of IFN-γ, IL-15, IL-17, and IL-22. *Journal of Investigative Dermatology* 133, 973–979 (2013).
30. Albesani, C. et al. IL-4 and IL-13 Negatively Regulate TNF-α and IFN-γ-Induced -Defensin Expression through STAT-6, Suppressor of Cytokine Signaling (SOCS)-1, and SOCS-3. *J. Immunol.* 179, 984–992 (2007).
31. Nomura, I. et al. Psoriasis: characterization of six different clinical phenotypes. *Journal of the American Academy of Dermatology* 60, 962–971 (2009).
32. Newcomb, D. C. et al. A Functional IL-13 Receptor Is Expressed on Polarized Murine CD4+ T Cell and IL-13 Signaling Attenuates Th17 Cytokine Production. *J. Immunol.* 182, 5317–5321 (2009).
33. Harrington, L. E., Mangan, P. R. & Weaver, C. T. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. *Current Opinion in Immunology* 18, 349–356 (2006).
34. Zhang, L., Yang, X. Q., Cheng, J., Hui, R. S. & Gao, T. W. Increased Th17 cells are accompanied by Foxp3+ Treg cell accumulation and correlated with psoriasis disease severity. *Clinical Immunology* 135, 108–117 (2010).
35. Sugiyama, H. et al. Dysfunctional Blood and Target Tissue CD4+CD25 high Regulatory T Cells in Psoriasis: Mechanism Underlying Unrestrained Pathogenic Effector T Cell Proliferation. *J. Immunol.* 174, 164–174 (2004).
36. Yang, L. et al. Impaired function of regulatory T cells in patients with psoriasis is mediated by phosphorylation of STAT3. *Journal of Dermatological Science* **81**, 85–92 (2016).
37. Goodman, W. A. et al. IL-6 Signaling in Psoriasis Prevents Immune Suppression by Regulatory T Cells. *J. Immunol.* **183**, 3170–3176 (2009).
38. Jorn Bovenschen, H. et al. Foxp3+ Regulatory T Cells of Psoriasis Patients Easily Differentiate into IL-17A-Producing Cells and Are Found in Lesional Skin. *Journal of Investigative Dermatology* **131**, 1853–1860 (2011).
39. Ortega, C. et al. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. *Journal of leukocyte biology* **86**, 435–443 (2009).
40. Di Meglio, P. & Duarte, J. H. CD8 T Cells and IFN–γ Emerge as Critical Players for Psoriasis in a Novel Model of Mouse Psoriasiform Skin Inflammation. *Journal of Investigative Dermatology* **133**, 871–874 (2013).
41. Suárez-Fariñas, M. et al. Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. *J. Invest. Dermatol.* **132**, 2552–2564 (2012).
42. Ahn, R. S. et al. Transcriptional landscape of epithelial and immune cell populations revealed through FACS-seq of healthy human skin. *Scientific Reports* **7**, 1828 (2017).
43. Grice, E. A. & Segre, J. A. The skin microbiome. *Nat Rev Micro* **9**, 244–253 (2011).
44. Adachi, T. et al. Hair follicle–derived IL-7 and IL-15 mediate skin-resident memory T cell homeostasis and lymphoma. *Nature Medicine* **21**, 1272–1279 (2015).
45. Christoph, T. et al. The human hair follicle immune system: cellular composition and immune privilege. *The British journal of dermatology* **142**, 862–873 (2000).

**Acknowledgements**

This study was supported by a Pfizer ASPIRE grant to W.L. R.A. acknowledges support from an NIAMS postdoctoral training grant to the Department of Dermatology at the University of California, San Francisco (T32 AR007175). The funding bodies played no role in the collection, analysis, or interpretation of data in this study.

**Author Contributions**

W.L. and M.R. designed the study and provided critical revisions of the manuscript. M.N. performed the skin biopsies. K.T., P.M.-S., S.B. and M.P. performed the flow cytometry. H.-W.C. and Z.-M.H. performed sample prep. D.Y., K.L., R.S. and L.A. recruited patients and compiled patient demographic data. D.Y. and H.-W.C. performed statistical analysis of the flow cytometry data. R.A. and H.-W.C. performed bioinformatic analysis of the RNA-seq data. R.A. and D.Y. jointly drafted the manuscript.

**Additional Information**

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-29472-w.

**Competing Interests:** The authors have the following interests: This study was funded by Pfizer, Inc.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018